Mate what are you still doing here replying to every post, every day 24/7... ?
If I thought the $3M was going to make a material difference I would have said. All comments regarding cash burn, their need to raise cash to complete the trial, and now current compromised position to do that. All still stand, and are a huge risk to shareholders.
Not sure company announcements you read. But as per the ASX. pre 02/09/2024 IMU decided Azercel mono flopped in initial phase 1. So they pivoted and opened a new trial phase 1B in combo with IL-2. Any phase 1 cohort A data (to use your term). Doesn't count towards the FDA submission of Azercel and IL-2. (So at minimum they need 3 more, ideally should be 15-20 patients). They haven't dosed anymore patients in cohort A. And why would you? (wasting time and money they don't have. Plus ethics of giving a inferior treatment to IL-2 + Azercel).
Moving along to phase 1B - 4 patients were enrolled in that September announcement. There is now 7 enrolments. That's 3 new patients since 2nd of September. Management are now saying they have 18 sites across USA and Australia accepting new enrolments.
Thats 7 patients off 18 hospitals. Why incur the cost on onboarding hospitals if you are then not going to use them? Second key failure, management are way too slow to complete trials and despite all the rosey promotion with shareholders are not able to drive engagement with clinicians at the ground level to enroll eligible patients to their trials. If the company needs to use billboards to recruit patients, something is very very wrong... Another F u to shareholders given their current tight finances.
Last key failure. Management had the goal of being the first Allogeneic Car T into a registrational trial. Azercel is not the only Allo Car T in trial. 12 months play from August 2023 purchase. Even if IMU can resolve the above mentioned issued, it's still probable they'll miss the boat and big pharma investment dollars will go to other Allo therapy's.
Not regretting my decision to sell last year.
Wishing remaining holders the best of luck.
Not advice, it's your money your decisions.
IMU Price at posting:
4.3¢ Sentiment: None Disclosure: Not Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)